Antitumor efficacy of varying doses of S63845 combined with venetoclax. (A) SU-DHL-6 cells were xenografted subcutaneously into NSG female mice. After 10 days, mice were randomly assigned into comparable groups (5 mice each) and treated with vehicle and combinations of venetoclax (100 mg/kg orally 5 times per week) with varying doses of S63845 (25 mg/kg 2, 3, and 5 times per week and 12.5 mg/kg IV 5 times per week) for 2 weeks. Mean volume and error bars representing SD from 5 different tumors are shown. By day 22 of treatment (day 20 for S63845 at 25 mg/kg 5 times per week condition), there is complete tumor regression in all treatment groups. A 2-way ANOVA was used to determine statistical significance between the first day of treatment and subsequent time points. (B) Tumor volumes in treatment groups from panel A on day 76, tumor regression is maintained only in the group treated with S63845 at 25 mg/kg 5 times per week plus venetoclax at 100 mg/kg 5 times per week. (C) Histogram depicting weight variation in SU-DHL-6 xenografts of different treatment groups on day 26 posttreatment relative to day 0. A 2-way ANOVA was used to determine statistical significance between the first day of treatment and subsequent time points. **P < .01; *P < .05.